Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Aug 11, 2023

Total Value ($000): $203,401 (100.0% shares, 0.0% debt)

Holdings (7)

PHVS Pharvaris N.V. 27.9%

Value ($000) $56,676 Shares 3,743,450 Est. Cost $28.56 Unrealized -66.3%

— Lyell Immunopharma, Inc. 15.2%

Value ($000) $30,846 Shares 9,700,000 Est. Cost $16.24 Unrealized —

— Kinnate Biopharma Inc. 14.4%

Value ($000) $29,305 Shares 9,671,643 Est. Cost $39.78 Unrealized —

ACRS Aclaris Therapeutics, Inc. 14.3%

Value ($000) $29,119 Shares 2,808,034 Est. Cost $15.18 Unrealized -40.4%

KURA Kura Oncology, Inc. 9.6%

Value ($000) $19,572 Shares 1,849,947 Est. Cost $20.39 Unrealized -42.0%

— Cymabay Therapeutics, Inc. 9.6%

Value ($000) $19,569 Shares 1,787,094 Est. Cost $3.49 Unrealized —

SNDX Syndax Pharmaceuticals, Inc. 9.0%

Value ($000) $18,314 Shares 875,000 Est. Cost $22.62 Unrealized -8.0%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	Pharvaris N.V.	3,743,450	$56,676	27.9%	$28.56	-66.3%	COM	N69605108
—	Lyell Immunopharma, Inc.	9,700,000	$30,846	15.2%	$16.24	—	COM	55083R104
—	Kinnate Biopharma Inc.	9,671,643	$29,305	14.4%	$39.78	—	COM	49705R105
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$29,119	14.3%	$15.18	-40.4%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$19,572	9.6%	$20.39	-42.0%	COM	50127T109
—	Cymabay Therapeutics, Inc.	1,787,094	$19,569	9.6%	$3.49	—	COM	23257D103
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$18,314	9.0%	$22.62	-8.0%	COM	87164F105